China Plasmid DNA Manufacturing Market - Databook 2025 to 2034

Rapid biotech growth, government backing, and rising gene therapy demand fuel China's plasmid DNA market amid cost and regulatory challenges.

Highlights of the China’s plasmid DNA Manufacturing Market

• By product, the viral vector segment underwent notable growth in the market during 2024.
• By product, the plasmid DNA segment is anticipated to expand rapidly.
• By application, the cell and gene therapy segment experienced significant expansion in the market.
• By application, the DNA vaccines segment is anticipated to demonstrate steady upward momentum during the forecast period.
• By disease, the infectious disease segment saw strong growth during the studied period.
• By disease, the cancer segment is expected to see notable performance in growth between 2025–2034.

Plasmid DNA manufacturing outfits have grown exponentially in China. The rapidly growing biotechnology industry in the Asia-Pacific region is being driven by companies based mainly in China and India. The China plasmid DNA manufacturing market is growing rapidly due to the investment and initiative by the government for the laboratories, clinical trials, and import of biotechnological products. Furthermore, the increase in awareness of advanced cell and gene therapy, biotechnological advancements in medicine, and strategic partnerships between big players for innovation in the industry contribute immensely to the growth in the China plasmid DNA manufacturing market.

Market Trends

• Rising demand for gene therapies and cell therapies: Demand for plasmid DNA increases with the increase in demand for gene and cell therapy due to its medicinal application in treatments like CAR-T and CRISPR. The increasing outsourcing of clinical trials and experimental treatments to the Asia Pacific region has led to significant industry expansion in China.
• Government initiatives: Government investments and initiatives in Asia-Pacific contribute to the development of biotech labs and the production of plasmid DNA to meet the rising patient demand.
• Technological advancements: An increase in technological advancements for the improvement in the production and manufacturing of plasmid DNA boosts the plasmid DNA manufacturing market growth.

Restraints

Regulatory challenges and high costs

The regulatory systems for medical testing in China are rigid and require rigorous documentation, quality testing, and safety validation from every company willing to set up their manufacturing unit for plasmid DNA. Furthermore, the lack of harmonized standards of quality measures across the whole nation, nonetheless the APAC region, makes it difficult for the plasma DNA to attain consistency in quality and purity. Such rigid regulations delay product launches and increase costs for new entrants in the China plasmid DNA manufacturing market. Increased costs hinder the growth of plasmid DNA manufacturing units and thus delay their adaptation towards advanced gene therapies like CRISPR.

Opportunity

Rising number of partnerships and collaborations

Partnerships and collaboration between large companies for research and development are rising with the increase in demand for healthcare services and medicine. Companies are collaborating to set up laboratories and clinics for the research and development of advanced gene and cell therapy. This contributes majorly to the market growth as the number of patients in China is rising, and so is the demand for plasma DNA to treat patients through advanced gene therapy.

Recent Developments in China’s Plasmid DNA Manufacturing Market:

• In April 2025, GenScript Biotech and NSG Bio Form agreed to form a strategic partnership to promote biotechnology innovation by providing exclusive preferential rates along with technical guidance from experienced scientists across its range of biotech services and products to NSG Bio residents.